BeyondSpring (BYSI) Cash from Operations (2016 - 2026)
BeyondSpring's (BYSI) quarterly Cash from Operations came in at -$3.8 million in Q2 2026, up 35.78% year-over-year from -$2.8 million in Q2 2025, and down 15.11% quarter-over-quarter from -$3.3 million in Q1 2026.
Powered by 
Analysis
BeyondSpring (BYSI) Cash from Operations (2016 - 2026) Analysis & Trends
BeyondSpring has disclosed Cash from Operations across 9 years of filings, most recently posting -$3.8 million for Q2 2026.
- In Q2 2026, Cash from Operations rose 35.78% year-over-year to -$3.8 million; the TTM figure through Jun 2026 stood at -$16.7 million (down 17.43% YoY), while the FY2025 annual figure was -$19.8 million, down 20.23% from the prior year.
- Cash from Operations came in at -$3.8 million for Q2 2026 at BeyondSpring, down from -$3.3 million in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of $982000.0 in Q4 2024 to a low of -$7.0 million in Q2 2024.
- Average Cash from Operations over 3 years is -$4.3 million, with a median of -$4.7 million recorded in 2024.
- Year-over-year, Cash from Operations slumped 660.49% in 2025 and surged 35.78% in 2026.
- Over 3 years, Cash from Operations stood at $982000.0 in 2024, then tumbled by 660.49% to -$5.5 million in 2025, then soared by 31.47% to -$3.8 million in 2026.
- Per Business Quant data, the three most recent Cash from Operations figures were -$3.8 million in Q2 2026, -$3.3 million in Q1 2026, and -$5.5 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 8.62 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 3.44 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 5.37 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 5.88 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 835.00 Mn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 3.44 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | -387.32 Mn |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 507.66 Mn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 313.60 Mn |
| 10 | BeyondSpring | 31.51 Mn | 31.51 Mn | - | -3.77 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.77 Mn |
| Mar 31, 2026 | -3.28 Mn |
| Dec 31, 2025 | -5.50 Mn |
| Sep 30, 2025 | -4.19 Mn |
| Jun 30, 2025 | -5.87 Mn |
| Mar 31, 2025 | -4.20 Mn |
| Dec 31, 2024 | 982,000.00 |
| Sep 30, 2024 | -5.17 Mn |
| Jun 30, 2024 | -6.99 Mn |
| Mar 31, 2024 | -5.27 Mn |
| Dec 31, 2021 | -16.92 Mn |
| Sep 30, 2021 | 2.83 Mn |
| Jun 30, 2021 | -14.21 Mn |
| Mar 31, 2021 | -18.94 Mn |
| Dec 31, 2020 | -6.96 Mn |
| Sep 30, 2020 | -11.46 Mn |
| Jun 30, 2020 | -14.27 Mn |
| Mar 31, 2020 | -11.05 Mn |
| Dec 31, 2019 | -12.68 Mn |
| Sep 30, 2019 | -22.38 Mn |